Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MST1R | Q04912 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26750756 | 1.00 | KMT2A (0.52) | KMT2ASMN1; SMN2KDM4ERAB9AMET | |
| SCHEMBL26750753 | 0.86 | KDM4E (0.53) | KMT2ASMN1; SMN2KDM4ERAB9AMET | |
| SCHEMBL9751 | 0.86 | KDM4E (0.70) | KMT2ASMN1; SMN2KDM4ERAB9AMET | |
| SCHEMBL9752 | 0.86 | KDM4E (0.70) | KMT2ASMN1; SMN2KDM4ERAB9AMET | |
| SCHEMBL30487516 | 0.84 | KDM4E (0.74) | KMT2ASMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL6070391 | 0.84 | KDM4E (0.74) | KMT2ASMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL29733054 | 0.84 | KDM4E (0.74) | KMT2ASMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL6070393 | 0.84 | KDM4E (0.74) | KMT2ASMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL30628952 | 0.82 | PTPN1 (0.48) | KMT2ASMN1; SMN2RAB9AMEN1NPC1 | |
| SCHEMBL26750709 | 0.82 | PTPN1 (0.48) | KMT2ASMN1; SMN2RAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519384-B1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORP (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4519384-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | Promega Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519385-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240191211-A1 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2023215497-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | KMT2A 2293/4885SMN1; SMN2 4845/4885KDM4E 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.